Replies to post #4703 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>is GTCB development limited by their cash in hand in anyways?<

With more cash they could do things somewhat differently, I suppose. But I think GTC has adequate liquidity to execute the business plan. From the 2Q07 CC (#msg-22015291, about 2/3 of the way down):

>>
We believe that our current cash resources will be sufficient to finance the Company well into the second half of 2008, beyond the value-creating events associated with the progress of our DIC clinical study in Europe, completion of our US Phase III clinical trial, and filing of the BLA for ATryn in hereditary deficiency.
<<